KRAS and thyroid cancer, nonmedullary, 2: RAS alterations can occur in 12.7% (8.5% NRAS, 3.5% HRAS, and 0.7% KRAS) of the PTC cohort, 40-50% of follicular thyroid carcinoma (FTC), and 20-25% of follicular adenomas [10].